Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

MSCA-ITN-2020. Consorcio busca socios industriales para acoger a un doctorando durante un programa de prácticas de 18 meses en el área de medicamentos de terapia avanzada (ATMP)/gemelos digitales

Resumen

Tipo:
Búsqueda de socios
Referencia:
RDDE20191118001
Publicado:
11/12/2019
Caducidad:
11/12/2019
Resumen:
Una universidad alemana coordina una propuesta para las redes de formación MSCA-ITN con el objetivo de explotar el potencial de estrategias asistidas por modelos (gemelos digitales) para el desarrollo de medicamentos de terapia avanzada (ATMP) de la próxima generación. La universidad busca empresas con experiencia en desarrollar ATMP, preferiblemente para terapia inmune antitumoral, interesadas en unirse al consorcio y acoger a un doctorando durante un programa de prácticas de 18 meses financiado por la UE. La fecha límite de la convocatoria es el 14 de enero de 2020 y el plazo para presentar expresiones de interés finaliza el 15 de diciembre de 2019. El proyecto comenzará en otoño de 2020.

Details

Tittle:
MSCA-ITN-2020: Consortium is looking for additional industrial partners to host a PhD student for 18 months internship in the area of ATMP (Advanced Therapy Medicinal Products)/Digital Twin
Summary:
A German university is coordinator of a proposal for MSCA-ITN training network with the overall aim to exploit the power of model-assisted strategies (Digital Twins) for the development of next generation ATMPs (Advanced Therapy Medicinal Products). Sought are companies with expertise in development of ATMPs, preferred in the anti-tumour immune therapy, to join consortium and host a PhD student for EU-funded 18 months internship.
Description:
Advanced Therapy Medicinal Products (ATMP) based on gene therapy, cell therapy or tissue-engineering have a vast potential to provide novel breakthroughs in meeting therapeutic needs. They offer multiple advantages such as a decentralized approach for the development and manufacturing of more targeted (personalized and precision) health therapies at an affordable cost.

The overall aim of the intended innovative training network (ITN) is to ensure the competition of the European biopharmaceutical industrial sector in the field of next generation medicines, as ATMPs using todays and tomorrows digitalization capabilities as captured in Digital Twins. Therefore, the intended project wants to shape young researchers to gain solid scientific experience in cross-sectoral fields (medicine, life science, engineering), while simultaneously developing domain based process digitalization skills in industry and business. A tailored integrated program will be established to provide a generation of highly skilled scientists and engineers co-trained by industry and world-leading research institutions, capable of developing fundamental understanding and technologies in the field and its implementation in the European market.

Early stage researchers (ESR) are enrolled in the new doctoral program and jointly supervised by the academic and non-academic partners. Within the project, PhD students work on bioprocess engineering, cell biology, modelling and simulation as well as data handling. Each PhD candidate will crucially gain cross-sectoral experience in an individual research project, with the main working period (36 months) of the ESR equally split into an academic and an industrial part of 18 months to be completed in two different countries.

Scientifically, the project will tackle the fundamental challenge of providing improved manufacturing processes by applying new computational tools known as multi faceted Digital Twin as "Process Development and Manufacturing Platform" (PDMP) for ATMPs. It will enable full integration of all the process steps, regulatory requirements and business process workflows involved in leap frogging new therapies to market in shorter times. The PDMP will be uniquely characterized by the use of current enablers of digitalization and Internet of Things (IoT) in the combination of process models and workflows, which assist in setting up and following up quality systems within a novel software architecture.

The consortium is composed of University Research teams and industrial partners with expertise on medical aspects of immune cell therapy, development of production processes for advanced therapies, model-assisted design of bioprocesses, development of data science methods for integrated and efficient bioprocess development along PAT (Process Analytical Technology) and QbD (Quality by Design) principles.

To complete the consortium, sought are additional industrial partners that are experienced in the development of ATMPs, preferred in anti-tumour immune therapy. Companies must be located in EU or eligible H2020 country. Within the project the industrial partners are expected to host a PhD student for 18 months and to participate in a training event. All costs for internship will be covered by the H2020 project.

For the proposal industrial partners are expected to contribute with
- A company profile.
- Description of experience with ATMPs and (if applicable) with mentoring of PhD students.
- Outline of a research project that the PhD candidate shall perform during internship at the company (to be defined before submission together with the research partner involved).

English is the spoken language within the project.

Expression of interest deadline: 15th of December 2019.
Call deadline: 14th of January 2020.
Consortium is planned to be finally composed by 20th of December 2019.
The project is applied for to start in autumn 2020.
Advantages and Innovations:
Industrial partners can

- Benefit from EU-funded 18 months internship of highly promising PhD candidates within the companies´ R-Y-D department

- Get involved in cutting-edge R-Y-D in the area of ATMP/Digital Twin

- Cooperate with a consortium of highly qualified research and industrial partners

- Work with a very experienced coordinator of EU-projects
Technical Specification or Expertise Sought:
Experience in the development of ATMPs, preferred in anti-tumor immune therapy. Experience with mentoring of PhD candidates would be beneficial but is not obligatory.

Partner sought

Partner Sought:
Type: Sought are pharmaceutical companies (SMEs or corporates) experienced in the development of ATMPs, preferred in anti-tumour immune therapy. Experience with mentoring of PhD candidates would be beneficial but are not obligatory. Companies must be located in EU or eligible H2020 country. Role: The company is expected to host a PhD student for at least 18 months and to participate in a training event. All costs for internship will be covered by the H2020 project.
Type of Partnership Considered:
RDR

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
German

Dissemination

Programme-call

Framwork Programme:
Marie Sklodowska-Curie Actions
Evaluation Scheme:
single-stage submission
Coordinator Required:
No
Deadline for Call:
14/01/2020